Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 68

1.

Assessing the Dynamics and Complexity of Disease Pathogenicity Using 4-Dimensional Immunological Data.

Rivas AL, Hoogesteijn AL, Antoniades A, Tomazou M, Buranda T, Perkins DJ, Fair JM, Durvasula R, Fasina FO, Tegos GP, van Regenmortel MHV.

Front Immunol. 2019 Jun 12;10:1258. doi: 10.3389/fimmu.2019.01258. eCollection 2019.

2.

Options and Limitations in Clinical Investigation of Bacterial Biofilms.

Magana M, Sereti C, Ioannidis A, Mitchell CA, Ball AR, Magiorkinis E, Chatzipanagiotou S, Hamblin MR, Hadjifrangiskou M, Tegos GP.

Clin Microbiol Rev. 2018 Apr 4;31(3). pii: e00084-16. doi: 10.1128/CMR.00084-16. Print 2018 Jul. Review.

3.

Attaching NorA efflux pump inhibitors to methylene blue enhances antimicrobial photodynamic inactivation of Escherichia coli and Acinetobacter baumannii in vitro and in vivo.

Rineh A, Bremner JB, Hamblin MR, Ball AR, Tegos GP, Kelso MJ.

Bioorg Med Chem Lett. 2018 Sep 1;28(16):2736-2740. doi: 10.1016/j.bmcl.2018.02.041. Epub 2018 Feb 24.

4.

High-Throughput Flow Cytometry Screening of Multidrug Efflux Systems.

Haynes MK, Garcia M, Peters R, Waller A, Tedesco P, Ursu O, Bologa CG, Santos RG, Pinilla C, Wu TH, Lovchik JA, Oprea TI, Sklar LA, Tegos GP.

Methods Mol Biol. 2018;1700:293-318. doi: 10.1007/978-1-4939-7454-2_16.

PMID:
29177837
5.

Attaching the NorA Efflux Pump Inhibitor INF55 to Methylene Blue Enhances Antimicrobial Photodynamic Inactivation of Methicillin-Resistant Staphylococcus aureus in Vitro and in Vivo.

Rineh A, Dolla NK, Ball AR, Magana M, Bremner JB, Hamblin MR, Tegos GP, Kelso MJ.

ACS Infect Dis. 2017 Oct 13;3(10):756-766. doi: 10.1021/acsinfecdis.7b00095. Epub 2017 Aug 17.

6.

Photoantimicrobials-are we afraid of the light?

Wainwright M, Maisch T, Nonell S, Plaetzer K, Almeida A, Tegos GP, Hamblin MR.

Lancet Infect Dis. 2017 Feb;17(2):e49-e55. doi: 10.1016/S1473-3099(16)30268-7. Epub 2016 Nov 22. Review.

7.

Pneumonia and Pleural Empyema due to a Mixed Lactobacillus spp. Infection as a Possible Early Esophageal Carcinoma Signature.

Chaini E, Chainis ND, Ioannidis A, Magana M, Nikolaou C, Papaparaskevas J, Liakata MV, Katopodis P, Papastavrou L, Tegos GP, Chatzipanagiotou S.

Front Med (Lausanne). 2016 Sep 28;3:42. eCollection 2016.

8.

Preventing Data Ambiguity in Infectious Diseases with Four-Dimensional and Personalized Evaluations.

Iandiorio MJ, Fair JM, Chatzipanagiotou S, Ioannidis A, Trikka-Graphakos E, Charalampaki N, Sereti C, Tegos GP, Hoogesteijn AL, Rivas AL.

PLoS One. 2016 Jul 13;11(7):e0159001. doi: 10.1371/journal.pone.0159001. eCollection 2016.

9.

Detecting the Hidden Properties of Immunological Data and Predicting the Mortality Risks of Infectious Syndromes.

Chatzipanagiotou S, Ioannidis A, Trikka-Graphakos E, Charalampaki N, Sereti C, Piccinini R, Higgins AM, Buranda T, Durvasula R, Hoogesteijn AL, Tegos GP, Rivas AL.

Front Immunol. 2016 Jun 10;7:217. doi: 10.3389/fimmu.2016.00217. eCollection 2016.

10.

Terms of endearment: Bacteria meet graphene nanosurfaces.

Tegou E, Magana M, Katsogridaki AE, Ioannidis A, Raptis V, Jordan S, Chatzipanagiotou S, Chatzandroulis S, Ornelas C, Tegos GP.

Biomaterials. 2016 May;89:38-55. doi: 10.1016/j.biomaterials.2016.02.030. Epub 2016 Feb 23. Review.

PMID:
26946404
11.

Therapeutic options and emerging alternatives for multidrug resistant staphylococcal infections.

Magana M, Ioannidis A, Magiorkinis E, Ursu O, Bologa CG, Chatzipanagiotou S, Hamblin MR, Tegos GP.

Curr Pharm Des. 2015;21(16):2058-72. Review.

PMID:
25760340
12.

Harnessing the power of light to treat staphylococcal infections focusing on MRSA.

Agrawal T, Avci P, Gupta GK, Rineh A, Lakshmanan S, Batwala V, Tegos GP, Hamblin MR.

Curr Pharm Des. 2015;21(16):2109-21. Review.

PMID:
25760339
13.

Versatile approaches to target staphylococcal infections.

Tegos GP.

Curr Pharm Des. 2015;21(16):2046-7. No abstract available.

PMID:
25760333
14.

Defining the microbial effluxome in the content of the host-microbiome interaction.

Ioannidis A, Magana M, Bologa CG, Oprea TI, Paulsen IT, Tegos GP.

Front Pharmacol. 2015 Feb 19;6:31. doi: 10.3389/fphar.2015.00031. eCollection 2015. No abstract available.

15.

A high throughput flow cytometric assay platform targeting transporter inhibition.

Tegos GP, Evangelisti AM, Strouse JJ, Ursu O, Bologa C, Sklar LA.

Drug Discov Today Technol. 2014 Jun;12:e95-103. doi: 10.1016/j.ddtec.2014.03.010. Review.

16.

Clostridium difficile infection: molecular pathogenesis and novel therapeutics.

Rineh A, Kelso MJ, Vatansever F, Tegos GP, Hamblin MR.

Expert Rev Anti Infect Ther. 2014 Jan;12(1):131-50. doi: 10.1586/14787210.2014.866515. Review.

17.

Biodefense: trends and challenges in combating biological warfare agents.

Tegos GP.

Virulence. 2013 Nov 15;4(8):740-4. doi: 10.4161/viru.27170. Epub 2013 Nov 14. No abstract available.

18.

Selective photoinactivation of Candida albicans in the non-vertebrate host infection model Galleria mellonella.

Chibebe Junior J, Sabino CP, Tan X, Junqueira JC, Wang Y, Fuchs BB, Jorge AO, Tegos GP, Hamblin MR, Mylonakis E.

BMC Microbiol. 2013 Oct 1;13:217. doi: 10.1186/1471-2180-13-217.

19.

Disruptive innovations: new anti-infectives in the age of resistance.

Tegos GP, Hamblin MR.

Curr Opin Pharmacol. 2013 Oct;13(5):673-7. doi: 10.1016/j.coph.2013.08.012. Epub 2013 Sep 5.

20.

Emerging trends in the discovery of natural product antibacterials.

Bologa CG, Ursu O, Oprea TI, Melançon CE 3rd, Tegos GP.

Curr Opin Pharmacol. 2013 Oct;13(5):678-87. doi: 10.1016/j.coph.2013.07.002. Epub 2013 Jul 24. Review.

21.

Photodynamic inactivation of biofilm: taking a lightly colored approach to stubborn infection.

de Melo WC, Avci P, de Oliveira MN, Gupta A, Vecchio D, Sadasivam M, Chandran R, Huang YY, Yin R, Perussi LR, Tegos GP, Perussi JR, Dai T, Hamblin MR.

Expert Rev Anti Infect Ther. 2013 Jul;11(7):669-93. doi: 10.1586/14787210.2013.811861. Review.

22.

Antimicrobial strategies centered around reactive oxygen species--bactericidal antibiotics, photodynamic therapy, and beyond.

Vatansever F, de Melo WC, Avci P, Vecchio D, Sadasivam M, Gupta A, Chandran R, Karimi M, Parizotto NA, Yin R, Tegos GP, Hamblin MR.

FEMS Microbiol Rev. 2013 Nov;37(6):955-89. doi: 10.1111/1574-6976.12026. Epub 2013 Jul 25. Review.

23.

Selective Efflux Inhibition of ATP-binding Cassette Sub-family G Member 2.

Strouse JJ, Ivnitski-Steele I, Njus HM, Foutz TD, Yao T, Weiner WS, Schroeder CE, Simpson DS, Maki BE, Li K, Golden JE, Waller A, Evangelisti AM, Young SM, Perez D, Chavez SE, Garcia MJ, Ursu O, Fara DC, Bologa CG, Carter MB, Salas VM, Tegos GP, Oprea TI, Edwards BS, Larson RS, Aubé J, Sklar LA.

Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2010-.
2010 Nov 30 [updated 2013 Feb 25].

24.

Microbial efflux systems and inhibitors: approaches to drug discovery and the challenge of clinical implementation.

Kourtesi C, Ball AR, Huang YY, Jachak SM, Vera DM, Khondkar P, Gibbons S, Hamblin MR, Tegos GP.

Open Microbiol J. 2013;7:34-52. doi: 10.2174/1874285801307010034. Epub 2013 Mar 22.

25.

Photodynamic and antibiotic therapy impair the pathogenesis of Enterococcus faecium in a whole animal insect model.

Chibebe Junior J, Fuchs BB, Sabino CP, Junqueira JC, Jorge AO, Ribeiro MS, Gilmore MS, Rice LB, Tegos GP, Hamblin MR, Mylonakis E.

PLoS One. 2013;8(2):e55926. doi: 10.1371/journal.pone.0055926. Epub 2013 Feb 14.

26.

Effect of virulence factors on the photodynamic inactivation of Cryptococcus neoformans.

Prates RA, Fuchs BB, Mizuno K, Naqvi Q, Kato IT, Ribeiro MS, Mylonakis E, Tegos GP, Hamblin MR.

PLoS One. 2013;8(1):e54387. doi: 10.1371/journal.pone.0054387. Epub 2013 Jan 18.

27.

Blue light rescues mice from potentially fatal Pseudomonas aeruginosa burn infection: efficacy, safety, and mechanism of action.

Dai T, Gupta A, Huang YY, Yin R, Murray CK, Vrahas MS, Sherwood ME, Tegos GP, Hamblin MR.

Antimicrob Agents Chemother. 2013 Mar;57(3):1238-45. doi: 10.1128/AAC.01652-12. Epub 2012 Dec 21.

28.

Antimicrobial photodynamic inactivation inhibits Candida albicans virulence factors and reduces in vivo pathogenicity.

Kato IT, Prates RA, Sabino CP, Fuchs BB, Tegos GP, Mylonakis E, Hamblin MR, Ribeiro MS.

Antimicrob Agents Chemother. 2013 Jan;57(1):445-51. doi: 10.1128/AAC.01451-12. Epub 2012 Nov 5.

29.

Ultraviolet C light for Acinetobacter baumannii wound infections in mice: potential use for battlefield wound decontamination?

Dai T, Murray CK, Vrahas MS, Baer DG, Tegos GP, Hamblin MR.

J Trauma Acute Care Surg. 2012 Sep;73(3):661-7.

30.

A selective ATP-binding cassette subfamily G member 2 efflux inhibitor revealed via high-throughput flow cytometry.

Strouse JJ, Ivnitski-Steele I, Khawaja HM, Perez D, Ricci J, Yao T, Weiner WS, Schroeder CE, Simpson DS, Maki BE, Li K, Golden JE, Foutz TD, Waller A, Evangelisti AM, Young SM, Chavez SE, Garcia MJ, Ursu O, Bologa CG, Carter MB, Salas VM, Gouveia K, Tegos GP, Oprea TI, Edwards BS, Aubé J, Larson RS, Sklar LA.

J Biomol Screen. 2013 Jan;18(1):26-38. doi: 10.1177/1087057112456875. Epub 2012 Aug 24.

31.

Blue light for infectious diseases: Propionibacterium acnes, Helicobacter pylori, and beyond?

Dai T, Gupta A, Murray CK, Vrahas MS, Tegos GP, Hamblin MR.

Drug Resist Updat. 2012 Aug;15(4):223-36. doi: 10.1016/j.drup.2012.07.001. Epub 2012 Jul 28. Review.

32.

A novel flow cytometric HTS assay reveals functional modulators of ATP binding cassette transporter ABCB6.

Polireddy K, Khan MM, Chavan H, Young S, Ma X, Waller A, Garcia M, Perez D, Chavez S, Strouse JJ, Haynes MK, Bologa CG, Oprea TI, Tegos GP, Sklar LA, Krishnamurthy P.

PLoS One. 2012;7(7):e40005. doi: 10.1371/journal.pone.0040005. Epub 2012 Jul 10.

33.

Dissecting novel virulent determinants in the Burkholderia cepacia complex.

Tegos GP, Haynes MK, Schweizer HP.

Virulence. 2012 May 1;3(3):234-7. doi: 10.4161/viru.19844. Epub 2012 May 1.

34.

Concepts and principles of photodynamic therapy as an alternative antifungal discovery platform.

Dai T, Fuchs BB, Coleman JJ, Prates RA, Astrakas C, St Denis TG, Ribeiro MS, Mylonakis E, Hamblin MR, Tegos GP.

Front Microbiol. 2012 Apr 10;3:120. doi: 10.3389/fmicb.2012.00120. eCollection 2012.

35.

Strategies to potentiate antimicrobial photoinactivation by overcoming resistant phenotypes.

Vera DM, Haynes MH, Ball AR, Dai T, Astrakas C, Kelso MJ, Hamblin MR, Tegos GP.

Photochem Photobiol. 2012 May-Jun;88(3):499-511. doi: 10.1111/j.1751-1097.2012.01087.x. Epub 2012 Feb 13. Review.

36.

Down-regulation of glutatione S-transferase α 4 (hGSTA4) in the muscle of thermally injured patients is indicative of susceptibility to bacterial infection.

Apidianakis Y, Que YA, Xu W, Tegos GP, Zimniak P, Hamblin MR, Tompkins RG, Xiao W, Rahme LG.

FASEB J. 2012 Feb;26(2):730-7. doi: 10.1096/fj.11-192484. Epub 2011 Oct 28.

37.

All you need is light: antimicrobial photoinactivation as an evolving and emerging discovery strategy against infectious disease.

St Denis TG, Dai T, Izikson L, Astrakas C, Anderson RR, Hamblin MR, Tegos GP.

Virulence. 2011 Nov-Dec;2(6):509-20. doi: 10.4161/viru.2.6.17889. Epub 2011 Nov 1. Review.

38.

Blue dye and red light, a dynamic combination for prophylaxis and treatment of cutaneous Candida albicans infections in mice.

Dai T, Bil de Arce VJ, Tegos GP, Hamblin MR.

Antimicrob Agents Chemother. 2011 Dec;55(12):5710-7. doi: 10.1128/AAC.05404-11. Epub 2011 Sep 19.

39.

Antimicrobial Photodynamic Therapy with Functionalized Fullerenes: Quantitative Structure-activity Relationships.

Mizuno K, Zhiyentayev T, Huang L, Khalil S, Nasim F, Tegos GP, Gali H, Jahnke A, Wharton T, Hamblin MR.

J Nanomed Nanotechnol. 2011 Apr 1;2(2):1-9.

40.

Influence of multidrug efflux systems on methylene blue-mediated photodynamic inactivation of Candida albicans.

Prates RA, Kato IT, Ribeiro MS, Tegos GP, Hamblin MR.

J Antimicrob Chemother. 2011 Jul;66(7):1525-32. doi: 10.1093/jac/dkr160. Epub 2011 Apr 26.

41.

Drug discovery of antimicrobial photosensitizers using animal models.

Sharma SK, Dai T, Kharkwal GB, Huang YY, Huang L, De Arce VJ, Tegos GP, Hamblin MR.

Curr Pharm Des. 2011;17(13):1303-19. Review.

42.

Synergistic combination of chitosan acetate with nanoparticle silver as a topical antimicrobial: efficacy against bacterial burn infections.

Huang L, Dai T, Xuan Y, Tegos GP, Hamblin MR.

Antimicrob Agents Chemother. 2011 Jul;55(7):3432-8. doi: 10.1128/AAC.01803-10. Epub 2011 Apr 18.

43.

Antimicrobial and efflux pump inhibitory activity of caffeoylquinic acids from Artemisia absinthium against gram-positive pathogenic bacteria.

Fiamegos YC, Kastritis PL, Exarchou V, Han H, Bonvin AM, Vervoort J, Lewis K, Hamblin MR, Tegos GP.

PLoS One. 2011 Apr 4;6(4):e18127. doi: 10.1371/journal.pone.0018127.

44.

Microbial efflux pump inhibition: tactics and strategies.

Tegos GP, Haynes M, Strouse JJ, Khan MM, Bologa CG, Oprea TI, Sklar LA.

Curr Pharm Des. 2011;17(13):1291-302. Review.

45.

Photodynamic therapy with a cationic functionalized fullerene rescues mice from fatal wound infections.

Lu Z, Dai T, Huang L, Kurup DB, Tegos GP, Jahnke A, Wharton T, Hamblin MR.

Nanomedicine (Lond). 2010 Dec;5(10):1525-33. doi: 10.2217/nnm.10.98.

46.

Ultraviolet-C irradiation for prevention of central venous catheter-related infections: an in vitro study.

Dai T, Tegos GP, St Denis TG, Anderson D, Sinofsky E, Hamblin MR.

Photochem Photobiol. 2011 Jan-Feb;87(1):250-5. doi: 10.1111/j.1751-1097.2010.00819.x. Epub 2010 Nov 12.

47.

Efflux pump inhibitor potentiates antimicrobial photodynamic inactivation of Enterococcus faecalis biofilm.

Kishen A, Upadya M, Tegos GP, Hamblin MR.

Photochem Photobiol. 2010 Nov-Dec;86(6):1343-9. doi: 10.1111/j.1751-1097.2010.00792.x. Epub 2010 Sep 22.

48.

Stable synthetic cationic bacteriochlorins as selective antimicrobial photosensitizers.

Huang L, Huang YY, Mroz P, Tegos GP, Zhiyentayev T, Sharma SK, Lu Z, Balasubramanian T, Krayer M, Ruzié C, Yang E, Kee HL, Kirmaier C, Diers JR, Bocian DF, Holten D, Lindsey JS, Hamblin MR.

Antimicrob Agents Chemother. 2010 Sep;54(9):3834-41. doi: 10.1128/AAC.00125-10. Epub 2010 Jul 12.

49.

Photodynamic inactivation of Acinetobacter baumannii using phenothiazinium dyes: in vitro and in vivo studies.

Ragàs X, Dai T, Tegos GP, Agut M, Nonell S, Hamblin MR.

Lasers Surg Med. 2010 Jul;42(5):384-90. doi: 10.1002/lsm.20922.

50.

Characterization of plant-derived saponin natural products against Candida albicans.

Coleman JJ, Okoli I, Tegos GP, Holson EB, Wagner FF, Hamblin MR, Mylonakis E.

ACS Chem Biol. 2010 Mar 19;5(3):321-32. doi: 10.1021/cb900243b.

Supplemental Content

Loading ...
Support Center